{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:28:59Z","timestamp":1778516939224,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0108656"],"award-info":[{"award-number":["JP24fk0108656"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20H00411"],"award-info":[{"award-number":["20H00411"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127670","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:33:02Z","timestamp":1756308782000},"page":"127670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative immunogenicity study of quartet and bifurcated tetravalent dengue virus envelope domain III displayed virus-like particle vaccine candidates in BALB\/c mice"],"prefix":"10.1016","volume":"63","author":[{"given":"Krishna Raja","family":"Muthuraman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirayu","family":"Boonyakida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enoch Y.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127670_bb0005","article-title":"Global dengue epidemic worsens with record 14 million cases and 9,000 deaths reported in 2024","volume":"107940","author":"Haider","year":"2025","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127670_bb0010","first-page":"311","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered","volume":"42","author":"Halstead","year":"1970","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.vaccine.2025.127670_bb0015","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1021\/acs.biomac.4c01831","article-title":"Tetravalent virus-like particles engineered to display envelope domain IIIs of four dengue serotypes in silkworm as vaccine candidates","volume":"26","author":"Muthuraman","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.vaccine.2025.127670_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2024.106543","article-title":"Expression of dengue capsid-like particles in silkworm and display of envelope domain III of dengue virus serotype 2","volume":"222","author":"Muthuraman","year":"2024","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2025.127670_bb0025","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41565-024-01655-9","article-title":"Proactive vaccination using multiviral quartet nanocages to elicit broad anti-coronavirus responses","volume":"19","author":"Hills","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0030","doi-asserted-by":"crossref","first-page":"1560330","DOI":"10.3389\/fcimb.2025.1560330","article-title":"Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity","volume":"15","author":"Liu","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.copbio.2021.09.012","article-title":"Virus-like particles against infectious disease and cancer: guidance for the nano-architect","volume":"73","author":"Hills","year":"2022","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2025.106762","article-title":"From Silkroad to bioroad-silkworm biotechnology","volume":"234","author":"Park","year":"2025","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2025.127670_bb0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2007.05.042","article-title":"Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus","volume":"366","author":"Gromowski","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127670_bb0055","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1128\/JVI.00606-08","article-title":"Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus","volume":"82","author":"Gromowski","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0060","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1128\/JVI.00432-07","article-title":"Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes","volume":"81","author":"Sukupolvi-Petty","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0065","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.1998.58.655","article-title":"Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice","volume":"58","author":"Simmons","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127670_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006191","article-title":"A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice","volume":"12","author":"Ramasamy","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127670_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micinf.2006.09.009","article-title":"The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry","volume":"9","author":"Chin","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127670_bb0080","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4269\/ajtmh.2008.79.353","article-title":"An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes","volume":"79","author":"Etemad","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127670_bb0090","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/JVI.73.3.2547-2551.1999","article-title":"PrM- and cell-binding domains of the dengue virus E protein","volume":"73","author":"Wang","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0095","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2025.127670_bb0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2025.127670_bb0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127670_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"key":"10.1016\/j.vaccine.2025.127670_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/BA20070098","article-title":"Improved expression of fusion protein using a cysteine- protease- and chitinase-deficient Bombyx mori (silkworm) multiple nucleopolyhedrovirus bacmid in silkworm larvae","volume":"49","author":"Park","year":"2008","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.vaccine.2025.127670_bb0120","series-title":"Preparation of Plasmid DNA by Alkaline Lysis with SDS","first-page":"2006","author":"Sambrook","year":"2006"},{"key":"10.1016\/j.vaccine.2025.127670_bb0125","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10529-016-2144-x","article-title":"Versatility of chitosan\/BmNPV bacmid DNA nanocomplex as transfection reagent of recombinant protein expression in silkworm larvae","volume":"38","author":"Kato","year":"2016","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.vaccine.2025.127670_bb0130","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s00705-017-3360-y","article-title":"A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses","volume":"162","author":"Valdes","year":"2017","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0135","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1021\/acs.biomac.5c00459","article-title":"Virus-like particle-based multiserotype quartet vaccine of dengue envelope protein domain III elicited potent anti-dengue responses","volume":"26","author":"Boonyakida","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.vaccine.2025.127670_bb0140","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00339-21","article-title":"Seroprevalence of flavivirus neutralizing antibodies in Thailand by high-throughput neutralization assay: endemic circulation of zika virus before 2012","volume":"6","author":"Yamanaka","year":"2021","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.127670_bb0145","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1016\/j.vaccine.2022.09.012","article-title":"Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies","volume":"40","author":"Yamanaka","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127670_bb0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319400121","article-title":"Identification and epidemiological study of an uncultured flavivirus from ticks using viral metagenomics and pseudoinfectious viral particles","volume":"121","author":"Kobayashi","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.127670_bb0155","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1016\/j.vaccine.2014.06.017","article-title":"Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays","volume":"32","author":"Yamanaka","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127670_bb0160","doi-asserted-by":"crossref","first-page":"16624","DOI":"10.1038\/s41598-018-34865-y","article-title":"High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon","volume":"8","author":"Matsuda","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127670_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002952","article-title":"Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development","volume":"8","author":"Salje","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127670_bb0170","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s00253-018-8822-y","article-title":"Dengue viruses and promising envelope protein domain III-based vaccines","volume":"102","author":"Fahimi","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erv.09.139","article-title":"Domain III of the envelope protein as a dengue vaccine target","volume":"9","author":"Guzman","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127670_bb0180","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1073\/pnas.0832193100","article-title":"A ligand-binding pocket in the dengue virus envelope glycoprotein","volume":"100","author":"Modis","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.127670_bb0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/viro.1998.9200","article-title":"Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus","volume":"246","author":"Roehrig","year":"1998","journal-title":"Jamaica Virology"},{"key":"10.1016\/j.vaccine.2025.127670_bb0190","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00705-013-1639-1","article-title":"A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates","volume":"158","author":"Chen","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0195","article-title":"Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127670_bb0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4269\/ajtmh.2006.74.266","article-title":"Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes","volume":"74","author":"Khanam","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127670_bb0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/dna.2006.0547","article-title":"Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein","volume":"26","author":"Chen","year":"2007","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0210","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1016\/j.vaccine.2010.10.004","article-title":"A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice","volume":"28","author":"Block","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127670_bb0215","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00705-010-0734-9","article-title":"Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus","volume":"155","author":"Lazo","year":"2010","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0220","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1038\/s41598-018-26904-5","article-title":"Dengue envelope-based \u2018four-in-one\u2019 virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice","volume":"8","author":"Rajpoot","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127670_bb0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/BA20080074","article-title":"Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice","volume":"52","author":"Lazo","year":"2009","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.vaccine.2025.127670_bb0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4269\/ajtmh.2001.65.159","article-title":"Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine","volume":"65","author":"Simmons","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127670_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.975398","article-title":"Serological cross-reactivity among common flaviviruses","volume":"12","author":"Chan","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2025.127670_bb0240","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","article-title":"Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization","volume":"25","author":"Gallichotte","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.127670_bb0245","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4269\/ajtmh.1995.53.432","article-title":"Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein","volume":"53","author":"Smucny","year":"1995","journal-title":"Am J Trop Med Hyg"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T03:54:32Z","timestamp":1765857272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"alternative-id":["S0264410X25009673"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127670","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative immunogenicity study of quartet and bifurcated tetravalent dengue virus envelope domain III displayed virus-like particle vaccine candidates in BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127670"}}